Quantcast

Latest Biosimilar Stories

2014-09-19 08:25:58

SAN DIEGO, Sept. 19, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today announced that it will be presenting at the 21(st) Annual NewsMakers in the Biotech Industry conference in New York. Bertrand Liang, chief executive officer of Pfenex, will provide an overview of the company's development programs and business strategy on...

2014-09-17 12:25:34

Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that among Crohn's disease/ulcerative colitis (CD/UC) patients eligible for biologic therapy, only a proportion of patients currently receive a biologic. Surveyed gastroenterologists cite patients' discomfort with biological therapy as the...

2014-09-16 12:30:11

The Imminent Entry of Biosimilars Will Constrain Sales of Branded Biologics and Premium-Priced Emerging Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 16, 2014 /PRNewswire/ -- Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion in 2013 to over $18.2 billion in 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. TNF-alpha inhibitors...

2014-09-11 23:02:29

Regulators, pharmaceutical, biotechnology and medical device industry leaders, innovators, thought leaders and other regulatory stakeholders will participate in the Regulatory Affairs Professionals Society’s signature annual event. Rockville, MD, USA (PRWEB) September 11, 2014 The practitioners of a profession that has a profound impact on healthcare around the world, but whose work is not well understood by the general public will gather in Austin, TX, this month when the Regulatory...

2014-09-10 20:24:21

LONDON, Sept. 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Biotech API Manufacturing Services: World Industry and Market 2014-2024https://www.reportbuyer.com/product/2006105/Biotech-API-Manufacturing-Services-World-Industry-and-Market-2014-2024.html Report DetailsOutsourced biopharma production - new analysis announcing revenue prospectsWhat's the outlook for making biological active pharma ingredients (APIs) under contract? Visiongain's new report...

2014-09-10 16:25:54

DALLAS, September 10, 2014 /PRNewswire/ -- According to the new market research report "Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food, Medical Food, Other Supplements, Device, Drug) - Global Forecast to 2023", published by MarketsandMarkets, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current...

2014-09-10 12:28:22

WASHINGTON, Sept. 10, 2014 /PRNewswire-USNewswire/ -- The following is a statement on behalf of RetireSafe: Dear Member of Congress; We write to you today to bring to your attention a critical safety issue that could affect all Americans, but especially those older Americans who rely on relatively new medicines called "biologics". RetireSafe, a 400,000-supporter strong nationwide advocacy organization for seniors, works hard to give a voice to retired Americans and those who hope to retire....

2014-09-10 08:31:13

IRVINE, Calif., Sept. 10, 2014 /PRNewswire/ -- Newly issued guidance by the Supreme Court has the potential to reshape the landscape of biologic drug and product commercialization, says Kyle J. Heppenstall, Managing Director of CompassX Consulting, a consultancy that focuses on architecting and executing strategies for Health executives. "Two recent Supreme Court decisions have emboldened the U.S. Patent and Trademark Office (USPTO) to announce that thousands of patents, if reviewed today,...

2014-09-08 16:25:38

ST. PAUL, Minn., Sept. 8, 2014 /PRNewswire/ -- Prime Therapeutics, LLC (Prime) has submitted comments to the U.S. Food and Drug Administration (FDA) in support of two citizen petitions on the naming of biosimilar drugs. Biosimilars are medically equivalent versions of biologics, used to treat complex illnesses such as cancer. The citizen petitions were filed in 2013 by the Generic Pharmaceutical Association (GPhA) and Novartis. The petitions urged the FDA to adopt a naming system...

2014-08-27 12:31:23

Current Prescribers of Biosimilars Choose Between Biosimilar Products Based on the Manufacturer, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 27, 2014 /PRNewswire/ -- Decision Resources Group finds that physicians surveyed across six different specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, endocrinology and nephrology) expect the robustness and number of clinical trials that a biosimilar has been assessed in to be the...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.